The progressive state tracking would not violate constraint conditions and all signals would be bounded when the parameter increases to infinitely great and approaches a certain value based on BLF. The control effectiveness of BLFs is verified by the comparative simulation results with quadratic Lyapunov functions (QLFs).
A barrier Lyapunov function (BLF) is a scalar function V(x), defined with respect to the system [mathematical expression not reproducible] on an open region D containing the origin, that is, continuous, positive definite, has continuous firstorder partial derivatives at every point of D, has the property V(x) [right arrow] [infinity] as x approaches the boundary of D, and satisfies V(x(t)) [less than or equal to] b [for all]t [greater than or equal to] 0 along the solution of [??]= f(x) for x(0) [member of] D and some positive constant b.
According to previous description, we can choose a BLF candidate as follows:
In this section, an adaptive controller is designed based on backstepping method by utilizing a BLF for systems (3).
Since [mathematical expression not reproducible] and choose the following BLF candidate:
), a marketer of hypothermic cell storage and cryopreservation freeze media, announced its CryoStor cell freeze media was used in a porcine animal study of umbilical cord blood-derived mononuclear cells (UBC-MNC) to evaluate the safety and feasibility of these cells for cardiac regeneration in pediatric congenital heart disease (CHD).
) said that Frederick, Md.-based RoosterBio, Inc., has adopted the company's CryoStor clinical grade cryopreservation freeze media to commercialize RoosterBio's human bone marrow-derived, adult mesenchymal stem cell (hMSC) products.
It was reported on Friday that United States-based BioLife Solutions' (BLFS
:OTCBB) HypoThermosol product will be embedded in the on-going United States and European clinical trials of Intercytex's ICX-RHY-013, a proprietary cell-based therapy.
), a developer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract media manufacturer, announced that its customer TiGenix NV (EURONEXT BRUSSELS: TIG) has completed a phase I clinical safety trial of its expanded adipose-derived stem cell platform incorporating BioLife's cGMP HypoThermosol cell/tissue storage/shipping medium.
), a manufacturer of clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, announced that its biopreservation technology is being used in more than 50 clinical trial-stage cellular therapies.
), a manufacturer of clinical grade biopreservation media products for cells and tissues, recently said a growing number of life science organizations are using the company's products, including HypoThermosol and/or CryoStor, to support the development of new regenerative medicine products and therapies.
Effective 26 March 2014, the company will list its common stock on the NASDAQ Capital Market under the same ticker symbol, BLFS